|
Paladin and Somaxon Announce Filing of New Drug Submission for Silenor(R)
MarketWatch (press release) If approved, Silenor(R) could be the first and only prescription product approved for the treatment of insomnia in Canada that is not a controlled substance. Paladin received rights to commercialize Silenor(R) in Canada, South America and Africa from … |
View full post on insomnia – Google News
